⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for ret alteration

Every month we try and update this database with for ret alteration cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)NCT04222972
RET-fusion Non ...
Lung Neoplasm
Carcinoma, Non-...
Respiratory Tra...
Thoracic Neopla...
Neoplasms by Si...
Neoplasms
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Disea...
Head and Neck N...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
Neoplasms, Germ...
Neoplasms, Nerv...
Pralsetinib
Carboplatin
Cisplatin
Pemetrexed
Pembrolizumab
Gemcitabine
Paclitaxel
Nab-Paclitaxel
18 Years - Hoffmann-La Roche
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)NCT03157128
Non-Small Cell ...
Medullary Thyro...
Colon Cancer
Any Solid Tumor
LOXO-292
12 Years - Eli Lilly and Company
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsNCT03899792
Medullary Thyro...
Infantile Myofi...
Infantile Fibro...
Papillary Thyro...
Soft Tissue Sar...
LOXO-292
6 Months - 21 YearsEli Lilly and Company
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationNCT04280081
Solid Tumor
Medullary Thyro...
Selpercatinib
18 Years - Eli Lilly and Company
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsNCT03037385
RET-altered Non...
Medullary Thyro...
RET-altered Pap...
RET-altered Col...
RET-altered Sol...
Lung Neoplasm
Carcinoma, Non-...
Thyroid Disease...
Thyroid Neoplas...
Thyroid Cancer,...
Carcinoma, Neur...
Respiratory Tra...
Thoracic Neopla...
Neoplasms by Si...
Neoplasms
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Endocrine Syste...
Endocrine Gland...
Head and Neck N...
Adenocarcinoma,...
Adenocarcinoma
Carcinoma
Neoplasms, Glan...
Neoplasms by Hi...
Neuroendocrine ...
Neuroectodermal...
Neoplasms, Germ...
Neoplasms, Nerv...
Colonic Neoplas...
Colorectal Neop...
Intestinal Neop...
Gastrointestina...
Digestive Syste...
Digestive Syste...
Gastrointestina...
Colonic Disease...
Intestinal Dise...
pralsetinib (BL...
18 Years - Hoffmann-La Roche
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsNCT03899792
Medullary Thyro...
Infantile Myofi...
Infantile Fibro...
Papillary Thyro...
Soft Tissue Sar...
LOXO-292
6 Months - 21 YearsEli Lilly and Company
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: